SCP
PLSE icon

Silverleafe Capital Partners’s Pulse Biosciences PLSE Stock Holding History

Silverleafe Capital Partners’s Portfolio PLSE Stock Details PLSE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-33,000
Closed -$500K – 64
2018
Q2 		$500K Buy
+33,000
New +$559K 0.31% 35

Other funds holding PLSE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
HCS
Harvest Capital Strategies San Francisco, California $73.7M AUM 7.47% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TF
TIAA FSB Jacksonville, Florida $27.6B AUM 14.26% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Silverleafe Capital Partners's PLSE Position: Q3 2018 in Review

Silverleafe Capital Partners sold out of Pulse Biosciences (PLSE) in Q3 2018, closing a stake of 33,000 shares — an estimated $500K sold.

Silverleafe Capital Partners first reported a position in PLSE in Q2 2018 and held it in 1 quarter. The position peaked at $500K in Q2 2018. 46 funds tracked by Wall St. Rank hold PLSE as of Q3 2018.

  • Silverleafe Capital Partners reported no remaining Pulse Biosciences position as of Q3 2018 after selling out during the quarter.
  • Silverleafe Capital Partners sold 33,000 Pulse Biosciences shares in Q3 2018, an estimated $500K.
  • Silverleafe Capital Partners first reported a position in Pulse Biosciences in Q2 2018 and held it in 1 quarter.
  • Silverleafe Capital Partners's Pulse Biosciences position peaked at $500K in Q2 2018.
  • 46 funds tracked by Wall St. Rank held Pulse Biosciences as of Q3 2018.

Based on Silverleafe Capital Partners's 13F filing for Q3 2018, filed 5 Oct 2018.